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Sub-protocol for assessing Patient Reported Outcomes            
and Quality of Life in the CONPET studya 
 
Henrik Eshøj, Pt., Ph.d., (Responsible for the components of this PRO protocol)1,2, Lene Kongsgaard 
Nielsen, MD, Ph.d. student1,2, Niels Abildgaard, MD, Professor1, Fredrik Schjesvold, MD, Ph.d.3 
 
1 
Quality of Life Research Center, Department of Haematology, Odense University Hospital, Odense, Denmark 
2 
OPEN, Odense Patient data Explorative Network, Odense University Hospital, Odense, Denmark 
3 
Department of Haematology, Oslo University Hospital, Oslo, Norway 
 
 
STUDY STRUCTURE and COLLABORATORS 
Fredrik Schjesvold, Department of Haematology, Oslo University Hospital is sponsor/principal 
Investigator (PI) of the CONPET study. PI is responsible for conducting the research project, except 
for the collection of patient reported outcome (PRO) data, which is managed by The Quality of Life 
Research Center (QLR), Department of Haematology, Odense University Hospital. This include 
design and description of a protocol for collecting PROs, development of a database to collect and 
store the PRO data, training of study nurses on how to comply with the PRO protocol. Any 




a NMSG25/16 – THE CONPET STUDY - KRd consolidation in multiple myeloma patients with a 
positive PET-CT after standard first line treatment” - a phase II clinical trial  
Clinicaltrials.gov.: NCT03314636 
EudraCT.: 2017-000586-72 




CONPET PROTOCOL SUMMARY 
Multiple Myeloma (MM) is the most common hematological malignancy after lymphoms. The 
overall survival (OS) of patients has doubled in the last 30 years from a median of 2−3 years to 4−6 
years in elderly patients, and up to 8−10 years for younger patients. The change in OS is mainly 
due to autologous stem cell transplantation (ASCT) combined with immunomodulatory drugs and 
proteasome inhibitors (1-3). However, following first-line therapy, most MM patients experience 
several relapses in the course of the disease.  An important predictor for overall survival is ´time to 
first relapse´. Recently, it has been shown, that PET-CT before maintenance after first-line 
treatment is the best predictor for OS (Moreau et al, ASH 2015, abstract 395). Patients with PET-CT 
positivity are therefore the focus of this study. The primary question to be answered is whether 
four 28-days cycles of Carfilzomib-Lenalidomide-Dexamethasone (KRd) consolidation after first 
line therapy can turn PET-CT positivity into negativity.  
The primary objectives of the current CONPET trial is to assess the proportion of multiple myeloma 
patients that are PET-CT positive after standard first line treatment, and, further, how many of 
these can become PET-CT negative after receiving four 28-day cycles of KRd consolidation 
treatment. Secondary objectives are to evaluate the effects of KRd treatment on health-related 
quality of life (QoL) collected through patient reported outcomes (PRO). This protocol describes 
the rationale, objectives and methods for collecting the PRO QoL data in the CONPET trial.  
 
 





Table 1. Assessment schedule of health-related quality of life through patient reported outcomes (PRO)
 
 PRO Instruments 
Screening Cycle 1 Cycle 2 Cycle 3 Cycle 4 1 month post 
Cycle 4 
3 month post 
Cycle 4 
End of study 
at PD 
Day 1 Day 15  Day 1  Day 15  Day 1 Dag 15  Day 1 Day 15     


























EORTC QLQ-CIPN-20 X X               X     
mth month; PD progressive disease; EORTC European Organisation for Research and Treatment of Cancer; QLQ Quality of Life Questionnaire; C30 30 items; FACT - PSI Functional 
Assessment of Cancer Therapy - Pulmonary Symptom Index, CIPN20 Chemotherapy-Induced Peripheral Neuropathy-20 items 




BACKGROUND and RATIONALE 
As a secondary outcome in the CONPET trial, PROs are used to extensively evaluate the health-
related QoL during and after consolidation with KRd treatment. Generally, there is a lack of PRO 
assessments within KRd treatment. As a consequence, patient-experienced side effects (SE) and 
adverse events (AE) of KRd are not well known. Lenalidomide is a immunomodulatory drug as 
Thalidomide, and Carfilzomib is a proteasome inhibitor as Bortezomib. Thalidomide and 
Bortezomib is known to induce peripheral neuropathy in up to 75% of patients treated with these 
drugs(4) . Further, a large proportion of the patients included in the CONPET trial have been 
treatedwith Bortezomib as part of their first-line treatment. Thus, KRd treatment is potentially 
neurotoxic. Though, large phase III randomized controlled clinical trials, using Lenalidomide and/or 
Carfilzomib as treatment for MM patients, did not find any increase in physician-reported 
peripheral neuropathy (5-9). However, it is well known, that symptomatic toxicity are 
underreported by physicians in clinical trials using the Common Terminology Criteria for Adverse 
Events (CTCAE) (10, 11) . One way to address this, is to collect data directly from patients 
themselves using PROs. Such PRO is the EORTC QLQ Chemotherapy Induced Peripheral 
Neuropathy Module 20 (CIPN20) (12). This questionnaire has been validated in MM patients 
showing that peripheral neuropaty has a negative impact on health-related QoL (13). Thus, it is 
highly important to investigate and report any occurrence of drug-induced toxicity with the use of 
PROs. However, chemotherapy induced peripheral neuropathy is yet to be assessed through PROs 
in MM patients.  
Other non-hematologic AEs are pneumonia and dyspnea in MM patients receiving Carfilzomib 
(14). Similar symptoms are reported in MM patients receiving Lenalidomide alone whereas 
cardiovascular complications, such as hypertension, pulmonary edema and thromboembolism are 
potential AEs in MM patients receiving Dexamethasone monotherapy. Finally, lenalidomide in 
combination with Dexamethasone has shown to increase the risk of venous and arterial 
thromboembolic events (15). To counteract such symptoms and events diuretic and anti-
hypertensive medication are commonly prescribed . Thus, patients that receive either of these  




products should be closely monitored in terms of shortness of breath, chest pain, arm or leg 
swelling.  
The aim of this study is to evaluate the effects of Carfilzomib, Lenalidomide, and Dexamethasone 
(KRd) treatment on secondary PRO endpoints in MM patients with a positive PET-CT after 




1. To determine the effects of KRd treatment on shortness of breath throughout the course 
of treatment (day 1 and 15 in each cycle) using the PRO FACT-PSI.  
2. To correlate the peripheral neuropathy scores obtained from the QLQ-CIPN20 with the 
global QoL domain of the QLQ-C30 at 1 month after completing the KRd treatment  
3. To assess the impact of KRd treatment on QoL using the QLQ-C30 global health status/QoL 
scale at day 15, cycle 4 and 1 month after completing the KRd treatment (1 month after C4) 
compared to baseline 
 
Secondary: 
1. To determine the use of anti-hypertensive and diuretic drugs during the course of KRD 
treatment (reported by study nurses)  
2. To correlate the use of anti-hypertensive and diuretic drugs with shortness of breath using 
the PRO FACT-PSI 
3. To correlate the shortness of breath score using the PRO FACT-PSI with the physical  
functioning domain of QLQ-C30. 
4. To correlate the peripheral neuropathy scores from the PRO QLQ-CIPN20 with the  
physician reported peripheral neuropathy  
5. To correlate the various QLQ-C30 sub-scale scores with the global QoL scale of QLQ-C30 
 





1. Patients report temporary clinically meaningful increased shortness of breath during KRd 
treatment compared to baseline 
2. Due to the course of KRD treatment with cycles of 28 days (21 days of active treatment, 
seven days pause) patients´ shortness of breath are less pronounced in the last seven days 
of each cycle. 
3. Peripheral neuropathy are increased compared to baseline at the one month follow-up 
after end of KRd consolidation treatment, but do not significantly effect global QoL (QLQ-
C30) compared to baseline values 
4. Patients report increased peripheral neuropathy through the PRO QLQ-CIPN20 compared 
to the physician-reported by by use of the CTCAE 
5. Patients show an increase in anti-hypertensive and/or diuretic drug use around the days of 
KRd treatment 
6. Shortness of breath has returned to normal level (baseline values) at the three months 
follow-up after end of consolidation treatment.  
7. Shortness of breath do not affect their self-reported physical functioning as measured with 
the QLQ-C30 domain.  
8. Patients do not report increased clinically meaningful peripheral neuropathy during the 
course of treatment.   
9. Peripheral neuropathy scores using the PRO QLQ-CIPN20 have returned to normal level 
(baseline values) at three months after starting the last cycle cycle of KRD treatment 
compared to baseline 
 
  





Eligibility criteria specific to PRO assessment 
The critera for in- and exclusion to the assessment of PROs are the same as described in the 
CONPET study protocol (appendix 1).  
 
Patient Reported Outcome Questionnaires 
European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life 
Questionnaire (EORTC QLQ-C30) (appendix 2) 
QLQ-C30 is a 30-item cancer-specific questionnaire composed by multi-item scales and single-
items scales (16). This includes five functional multi-item scales (physical, cognitive, emotional, 
social and role functioning), three multi-item symptom scales (pain, fatique and nausea/vomiting), 
a global health status/QoL scale and six single-items assessing additional symptoms (dyspnea, 
insomnia, appetite loss, constipation, diarrhoea and financial difficulties). Each scale is scored from 
0-100, and for the global QoL and functional scales, a higher score means a better functioning, and 
for the symptom scales, a higher score means higher degree of symptoms (17). The QLQ-C30 is 
reliable and valid for use in myeloma patients (18). The QLQ-C30 is chosen as it contains scales of 
physical functioning and global QoL that is to be used to correlate with the other specific PROs. 
 
Functional Assessment of Cancer Therapy - Pulmonary Symptom Index (FACT-PSI) (appendix 3) 
The FACT-PSI is a 4-item cancer specific symptom index questionnaire developed for patients with 
lung cancer. Items are equally weighted and scored on a 0-4 scale with total FACT-PSI score 
ranging from 0-16 (16=asymptomatic)(19). FACT-PSI is cross-culturally translated into Danish, 
Swedish and Norwegian by the FACIT Measurement System (www.facit.org). FACT-PSI has not 
been used on MM patients, but is validated on cancer patients receiving second- and third-line 
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treatment for advanced non-small-cell-lung cancer (20). FACT-PSI is chosen since the time to 
completion is short (4 items only) and that it is directed specifically towards shortness of breath.  
 
EORTC QLQ Chemotherapy-Induced Peripheral Neuropathy Module 20 (QLQ-CPIN20) (appendix 4) 
The CIPN20 is a 20-item QoL questionnaire developed to elicit patients' experience of symptoms 
and functional limitations related to chemotherapy-induced pheripheral neuropathy. The CIPN20 
has 3 subscales: a sensory, a motor, and an autonomic subscale.The questionnaire is a valid 
instrument to distinguish between higher and lower CIPN in MM patients necessery to dedice on 
dose modification of chemotherapy in clinical practice (13). The CIPN20 is expected to yield a 
more complete picture of the nature, frequency, and severity of CIPN compared to the more 
classical, physician-based clinical rating scales.  
 
Treatment schedule  
Treatment with intravenous infusion of Carfilzomib is scheduled day 1, 2, 8, 9, 15 and 16 i cycles of 
28 days, repeated four times. Dose escalation is performed in cycle 1. Oral Lenalidomide is 20 mg 
on days 1-21 in each of the four cycles. Oral Dexamethason is 40 mg weekly throughout the study.  
 
PRO Assessment and Time Points  
QoL data, using the PROs EORTC QLQ-C30 and FACT-PSI, are obtained at baseline 
(=screeningsperiod), day 1 and 15 in each treatment cycle, besides 1 and 3 months after the last 
day of cycle 4 and at “End Of Treatment“ (equal to progressive disease, withdrawel of participant 
consent, side effects not compatible with continuation in the study or medical conditions that 
require treatment to be stopped). Data on peripheral neuropathy using the EORTC-CIPN20 
questionnaire are to be collected at the following time points; baseline, day 1, cycle 1 and 1 month 
after the last day of cycle 4 (Table 1).   
 
 




Administration of the PRO data assessment  
A study nurse from each of the participating sites will be responsible for collecting the PRO data. 
The PRO data will be collected electronically by use of a tablet, handed to the patient, at the 
outpatient clinic during the scheduled intravenous infusion of Carfilzomib (KRd treatment) (day 1 
and 15 in each cycle) as described in table 1. In case of failure with the electronic equipment (e.g. 
tablet is out of power, wireless internet out of function, ect.) hard copies of the PRO 
questionnaires will be used to collect data.  
Timing of PRO data collection 
Collection of PRO data follows the scheduled visits as described in table 1. Therefore, if an 
otherwise scheduled KRd treatment is cancelled/rescheduled so will the collection of PRO data be. 
However, the responsible study nurse is required to report the reasons why the PRO assessment 
was not obtained as scheduled using the below options:  
 
 Due to public holiday 
 Due to side effects and/or treatment complications (e.g. concomitant pneumonia) 
 Due to patient wish 
 Other reason, please specify 
 
If a scheduled treatment, and thus also the accompanying scheduled PRO data collection, is re-
scheduled the responsible study nurse is required to report the number of days from the 
scheduled PRO data assessment and to the actual PRO data assessment, using the below options:  
 1-3 days 
 4-7 days 
 8-15 days 
 16-21 days 




 22-31 days 
 1-2 months 
 >2 months  
 
Actions to minimize missing data 
If collection of PRO data is missed (for whatever reason) at the day of KRd treatment (day 1 and 15 
in each cycle, table 1) alternative PRO completion methods will be used. The time window for 
completing QoL assessment in alternative ways is no more than 2 working days from the day that 
the scheduled QoL assessment was missed. This means, that if a QoL assessment is scheduled to 
be performed on a Tuesday, the alternative QoL assessment should be completed no later than 
Thursday the same week. The study nurse is required to try and contact/call the patient at least 
twice a day for two consecutive days from the scheduled PRO data collection that was missed.  
 
The PRO data can be obtained alternatively as follows:  
 
 According to the treatment schedule, the patient will be in for intravenous Carfilzomib 





 The PRO data may be completed by telephone (study nurse complete the questionnaires 




 The PRO data may be collected through email (a PDF version of the PROs will be emailed to 
the patient. The patient complete the questionnaires within a maximum of two days from  




the scheduled PRO data assessment. The patient returns the questionnaires to the study  
nurse at the next treatment visit)  
 
If the patient cannot be reached or that the patient is unwilling to complete PRO data in 
alternative ways the collection of PRO data will be missed. The reasons why PRO data are missing 
is reported by the study nurse.  
 
Monitoring of compliance with the PRO data 
The QLR will monitor that the procedures above are followed. If not, the QLR contacts the study 
nurse responsible for the specific PRO data collection to make sure that procedures regarding 
future QoL assessments are followed.  
 
Information on the Course of Treatment  
The responsible study nurse is required to monitor the course of KRd treatment continously at day 
1 and 15 in each cycle with regards to the use of diuretic and anti-hypertensive drug. If any of 
these medicaments are used by the patient the study nurse will register dose and frequency of 
intake within the last seven days from the KRd treatments at day 1 and 15. These informations will 
be used to interpret the health-related PRO scores obtained by the questionnaires through the 
course of KRd treatment. 
 
Training of staff to collect PRO data  
Online video material/guidelines on how to collect the PRO data and how to use the QoL eCRF is 
provided to the study nurses prior to inclusion of patients. Online material/guidelines are located 
at www.screencast-o-matic.com. Study nurses are encouraged to look through the material and 
also to upload at least one pilot patient into the QoL eCRF before enrollment of patients begins.  
 





The PRO data will be stored on a secure server under the Region of Southern Denmark. The 
REDCap database (21) is used as platform for the PRO data, for which there also is a license 
agreement with Odense Patient Explorative Network (OPEN) at Odense University Hospital, 
Odense, Denmark. A data processor agreement is entered between the primary investigator and 
the Quality of Life Research Center, Odense University Hospital. This is to ensure that the rules of 
processing of personal data are followed at any given time point.  
 
STATISTICAL CONSIDERATIONS 
The present PRO protocol is not covered by sample size calculations for the main trial. The 
reporting of PRO data may thus only be describing/exploratory/hypothesis generating. However, 
by prespecifying PRO key domains and time points for primary analysis in the current PRO protocol 
risk of type 1 errors (multible statistical testing) is limited. Using PROs as described above, 
fluctuations in health-related QoL during the KRd treatment will be captured. Among other, 
comparison of health-related QoL scores between patients that are PET-CT positive and those that 
are PET-CT negative will be possible as well as changes in health-related QoL prior to and after 
recieving a PET-CT positive diagnose.  
Scoring manuals from the EORTC QLQ-C30 and QLQ-CIPN20 besides FACT-PSI will be used to 
calculate sumscores for each of the instruments and their subscales. Demographic (age, gender) 
and clinical charactheristics (medical history, symptoms, performance status) will be derived from 
the CONPET eCRF clinical database.  
A detailed statistical analysis plan (SAP) will be developed and made publicly available prior to the 
last included patient. Herein, handling of missing data as well as statistically methods used to 
analyse the PRO data will be described.  
Primary PRO analysis time point   
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In each treatment cycle, “shortness of breath” will be analysed by comparing the FACT-PSI score 
on day 1 and 15 to the baseline FACT-PSI score. Due to the course of treatment higher FACT-PSI 
scores are expected at day 15 compared to day 1. 
The primary analysis of peripheral neuropathy is prespecified to 1 month after the last day of cycle 
4.  












Appendices 1: Participant eligibility criteria for the CONPET trial  
Appendices 2: EORTC QLQ-C30 
Appendices 3: EORTC CIPN20 
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Appendices 1 (STUDY POPULATION) 
 
9.1 Inclusion criteria  
Each patient must meet all the following inclusion criteria to be enrolled in the study:   
1. At least 18 years of age, with at least 6 months expected survival.  
 
2. Prior confirmed diagnosis of multiple myeloma.  
3. Received standard first line treatment with at least a very good partial response (VGPR). 
Standard first line treatment is defined as  
• VRD, VTD or VCD followed by ASCT  
• MPV at least 6 cycles, or no further reduction in monoclonal component 
the last 2 cycles, or  
• Rd at least 9 cycles or no further reduction in monoclonal component the 
last 2 cycles.  
• VRd at least 6 cycles or no further reduction in monoclonal component 
the last 2 cycles  
4. Patients must be carfilzomib naive.  
 
5. Successful FISH evaluation performed with available results.  
 
6. Voluntary written consent must be given before performance of any study related 
procedure not part of standard medical care, with the understanding that the patient may 
withdraw consent at any time without prejudice to future medical care.  
 
7. Females of childbearing potential (FCBPs) must have a confirmed negative serum 
pregnancy test within the 7 days prior to inclusion  
 
8. FCBPs and male subjects who are sexually active with FCBP must agree to use highly 
effective concomitant methods of contraceptive during the study and for 30 days following 
the last study drug dose. Male subjects must use contraception and refrain from donating 
sperm for at least 90 days after the last dose of carfilzomib.  
 
9. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. In patients >75 
years of age, performance status 0-1.  
 
10. Patients must meet the following adequate organ and bone marrow function within 21 days 
prior to inclusion:  
 
• Absolute neutrophil count (ANC) ≥ 0,5 x 109/L) and platelet count 35 x 109/L. 
Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 
days before study enrollment. Granulocyte growth factors are allowed to meet the 
inclusion criteria.  
 
11. Patient must be willing and able to adhere to the study schedule and other protocol 
requirements.  
9.2 Exclusion criteria  
Patients meeting any of the following exclusion criteria are not to be enrolled in the study:  
 
1. Change of first line treatment because of stabile or progressive disease.  
2. Female patients who are lactating or have a positive serum pregnancy test during the 
screening period.  
3. Major surgery within 28 days before enrollment.  
4. Radiotherapy within 14 days before enrollment.Glucocorticoid therapy within the 14 days 
prior to inclusion that exceeds a cumulative dose of 160 mg dexamethasone or 1000 mg 
prednisone.  
5. Central nervous system involvement.  
6. Uncontrolled heart disease, including congestive heart failure (NYHA III-IV), uncontrolled 
angina pectoris, uncontrolled conduction abnormalities, acute diffuse infiltrative 
pulmonary disease, pericardial disease or myocardial infarction within 6 months prior to 
enrollment  
7. Active hepatitis B or C infection, or known human immunodeficiency virus (HIV) 
positivity.  
8. Any other serious medical or psychiatric illness that could, in the investigator’s opinion, 
potentially interfere with the completion of treatment according to this protocol.  
9. Known allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib) or to 
any of the study medications, their analogues, or excipients in the various formulations of 
any agent.  
10. Contraindication to dexamethasone or any of the required concomitant drugs or supportive 
treatments, including hypersensitivity to antiviral drugs, or intolerance to hydration due to 
pre-existing pulmonary or cardiac impairment.  
11. Another active malignancy. Patients with non-melanoma skin cancer or carcinoma in situ 
of any type are not excluded if they have undergone complete resection.  
12. Patients that have previously been treated with carfilzomib.  
13. Primary plasma cell leukemia, systemic AL amyloidosis, Waldenströms 
macroglobulinemia, POEMS syndrome.  
 
14. Pleural effusions requiring thoracocentesis within the 14 days prior the inclusion.  
 
15. Ascites requiring ascites puncture within the 14 days prior to inclusion.  
 
16. Previous allogeneic transplantation  
 
17. Uncontrolled hypertension or uncontrolled diabetes despite medication  
 




EORTC QLQ-C30 (version 3.0) 
 
Vi er interesserede i at vide noget om dig og dit helbred. Vær venlig at besvare alle spørgsmålene selv ved at sætte en 
ring omkring det svar (tal), som passer bedst på dig. Der er ingen "rigtige" eller "forkerte" svar. De oplysninger, som 
du giver os, vil forblive strengt fortrolige. 
 
Skriv venligst dine forbogstaver her:  
Din fødselsdato (dag, måned, år):  
Dato for udfyldelse af dette skema (dag, måned, år): 31  
  
  Slet 
  ikke Lidt En del Meget 
1. Har du nogen vanskeligheder ved at udføre anstrengende aktiviteter,  
som f.eks. at bære en tung indkøbstaske eller en kuffert? 1 2 3 4 
2. Har du nogen vanskeligheder ved at gå en lang tur? 1 2 3 4 
3. Har du nogen vanskeligheder ved at gå en kort tur udendørs? 1 2 3 4 
4. Er du nødt til at ligge i sengen eller sidde i en stol om dagen? 1 2 3 4 
5. Har du brug for hjælp til at spise, tage tøj på,  
 vaske dig eller gå på toilettet? 1 2 3 4 
 
I den forløbne uge: Slet 
  ikke Lidt En del Meget  
6. Var du begrænset i udførelsen af enten dit arbejde 
 eller andre daglige aktiviteter? 1 2 3 4 
7. Var du begrænset i at dyrke dine hobbyer eller andre fritidsaktiviteter? 1 2 3 4 
8. Havde du åndenød? 1 2 3 4 
9. Har du haft smerter? 1 2 3 4 
10. Havde du brug for at hvile dig? 1 2 3 4 
11. Har du haft søvnbesvær? 1 2 3 4 
12. Har du følt dig svag? 1 2 3 4 
13. Har du savnet appetit? 1 2 3 4 
14. Har du haft kvalme? 1 2 3 4 
15. Har du kastet op? 1 2 3 4 
16. Har du haft forstoppelse? 1 2 3 4 
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I den forløbne uge: Slet 
  ikke Lidt En del Meget 
 
17. Har du haft diarré (tynd mave)? 1 2 3 4 
18. Var du træt? 1 2 3 4 
19. Vanskeliggjorde smerter dine daglige gøremål? 1 2 3 4 
20. Har du haft svært ved at koncentrere dig om ting som 
 f.eks. at læse avis eller se fjernsyn? 1 2 3 4 
21. Følte du dig anspændt? 1 2 3 4 
22. Var du bekymret? 1 2 3 4 
23. Følte du dig irritabel? 1 2 3 4 
24. Følte du dig deprimeret? 1 2 3 4 
25. Har du haft svært ved at huske?  1 2 3 4 
26. Har din fysiske tilstand eller medicinske behandling 
 vanskeliggjort dit familieliv? 1 2 3 4 
27. Har din fysiske tilstand eller medicinske behandling 
 vanskeliggjort din omgang med andre mennesker? 1 2 3 4 
28. Har din fysiske tilstand eller medicinske behandling 
 medført økonomiske vanskeligheder for dig? 1 2 3 4 
 
Ved de næste 2 spørgsmål bedes du sætte en ring omkring det tal mellem 1 og 7, som 
passer bedst på dig 
 
29. Hvordan vil du vurdere dit samlede helbred i den forløbne uge? 
 
1 2 3 4 5 6 7 
 
 Meget dårligt                Særdeles godt    
 
 
30. Hvordan vil du vurdere din samlede livskvalitet i den forløbne uge? 
 
1 2 3 4 5 6 7 
 




EORTC QLQ-C30 (versjon 3.0.) 
 
Vi er interessert i forhold vedrørende deg og din helse. Vær så vennlig å besvare hvert spørsmål ved å sette 
en ring rundt det tallet som best beskriver din tilstand. Det er ingen "riktige" eller "gale" svar. Alle 
opplysningene vil bli behandlet konfidensielt. 
 
Ditt navns forbokstaver:  
Født (dag, mnd, år):  
Dato (dag, mnd, år): 31  
  
 Ikke i det   Svært 
 hele tatt Litt En del mye 
1. Har du vanskeligheter med å utføre anstrengende  
 aktiviteter, slik som å bære en tung handlekurv  
 eller en koffert? 1 2 3 4 
 
2. Har du vanskeligheter med å gå en lang tur?  1 2 3 4 
 
3. Har du vanskeligheter med å gå en kort tur utendørs? 1 2 3 4 
 
4. Er du nødt til å ligge til sengs eller sitte i en stol  
 i løpet av dagen? 1 2 3 4 
 
5. Trenger du hjelp til å spise, kle på deg, vaske deg  
 eller gå på toalettet? 1 2 3 4 
 
 
I løpet av den siste uken: Ikke i det   Svært 
 hele tatt Litt En del mye 
 
6. Har du hatt redusert evne til å arbeide eller 
 utføre andre daglige aktiviteter?  1 2 3 4 
 
7. Har du hatt redusert evne til å utføre dine  
 hobbyer eller andre fritidsaktiviteter?  1 2 3 4 
 
8. Har du vært tung i pusten?  1 2 3 4 
 
9. Har du hatt smerter?  1 2 3 4 
 
10. Har du hatt behov for å hvile?  1 2 3 4 
 
11. Har du hatt søvnproblemer?  1 2 3 4 
 
12. Har du følt deg slapp?  1 2 3 4 
 
13. Har du hatt dårlig matlyst?  1 2 3 4 
 
14. Har du vært kvalm?  1 2 3 4 
 




I løpet av den siste uken: Ikke i det   Svært 
 hele tatt Litt En del mye 
 
15. Har du kastet opp?  1 2 3 4 
 
16. Har du hatt treg mage?  1 2 3 4 
 
17. Har du hatt løs mage?  1 2 3 4 
 
18. Har du følt deg trett?  1 2 3 4 
 
19. Har smerter påvirket dine daglige aktiviteter?  1 2 3 4 
 
20. Har du hatt problemer med å konsentrere deg,  
 f.eks. med å lese en avis eller se på TV? 1 2 3 4 
 
21. Har du følt deg anspent?  1 2 3 4 
 
22. Har du vært engstelig?  1 2 3 4 
 
23. Har du følt deg irritabel?  1 2 3 4 
 
24. Har du følt deg deprimert?  1 2 3 4 
 
25. Har du hatt problemer med å huske ting?  1 2 3 4 
 
26. Har din fysiske tilstand eller medisinske behandling  
 påvirket ditt familieliv?  1 2 3 4 
 
27. Har din fysiske tilstand eller medisinske behandling 
 påvirket dine sosiale aktiviteter?  1 2 3 4 
 
28. Har din fysiske tilstand eller medisinske behandling  
 gitt deg økonomiske problemer?  1 2 3 4 
 
 
Som svar på de neste spørsmålene, sett en ring rundt det tallet fra 1 til 7  
som best beskriver din tilstand 
 
29. Hvordan har din helse vært i løpet av den siste uken? 
  
 1 2 3 4 5 6 7 
 
 Svært dårlig      Helt utmerket 
 
30. Hvordan har livskvaliteten din vært i løpet av den siste uken? 
 
 1 2 3 4 5 6 7 
 
 Svært dårlig      Helt utmerket 
 
 




EORTC QLQ-C30 (version 3) 
 
Vi är intresserade av några saker som har med dig och din hälsa att göra. Besvara alla frågor genom att sätta en ring 
runt den siffra som stämmer bäst in på dig. Det finns inga svar som är "rätt" eller "fel". Den information du lämnar 
kommer att hållas strikt konfidentiell. 
 
Fyll i Dina initialer:  
När är Du född? (Dag, Månad, År):  
Dagens datum (Dag, Månad, År): 31  
  
  Inte Lite En hel Mycket 
  alls  del  
1. Har du svårt att göra ansträngande saker, som att  
 bära en tung kasse eller väska? 1 2 3 4 
 
2. Har du svårt att ta en lång promenad? 1 2 3 4 
 
3. Har du svårt att ta en kort promenad utomhus? 1 2 3 4 
 
4. Måste du sitta eller ligga på dagarna? 1 2 3 4 
 
5. Behöver du hjälp med att äta, klä dig, tvätta dig  
 eller gå på toaletten? 1 2 3 4 
 
Under veckan som gått: Inte Lite En hel Mycket 
  alls  del  
6. Har du varit begränsad i dina möjligheter att utföra  
 antingen ditt förvärvsarbete eller andra dagliga aktiviteter? 1 2 3 4 
 
7. Har du varit begränsad i dina möjligheter att utöva  
 dina hobbyer eller andra fritidssysselsättningar? 1 2 3 4 
 
8. Har du blivit andfådd? 1 2 3 4 
 
9. Har du haft ont? 1 2 3 4 
 
10. Har du behövt vila? 1 2 3 4 
 
11. Har du haft svårt att sova? 1 2 3 4 
 
12. Har du känt dig svag? 1 2 3 4 
 
13. Har du haft dålig aptit? 1 2 3 4 
 
14. Har du känt dig illamående? 1 2 3 4 
 
15. Har du kräkts? 1 2 3 4 
 
16. Har du varit förstoppad? 1 2 3 4 
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Under veckan som gått: Inte Lite En hel Mycket 
  alls  del  
 
17. Har du haft diarré? 1 2 3 4 
 
18. Har du varit trött? 1 2 3 4 
 
19. Har dina dagliga aktiviteter påverkats av smärta? 1 2 3 4 
 
20. Har du haft svårt att koncentrera dig, t.ex. läsa 
 tidningen eller se på TV? 1 2 3 4 
 
21. Har du känt dig spänd? 1 2 3 4 
 
22. Har du oroat dig? 1 2 3 4 
 
23. Har du känt dig irriterad? 1 2 3 4 
 
24. Har du känt dig nedstämd? 1 2 3 4 
  
25. Har du haft svårt att komma ihåg saker?  1 2 3 4 
 
26. Har ditt fysiska tillstånd eller den medicinska 
 behandlingen stört ditt familjeliv? 1 2 3 4 
 
27. Har ditt fysiska tillstånd eller den medicinska 
 behandlingen stört dina sociala aktiviteter? 1 2 3 4 
 
28. Har ditt fysiska tillstånd eller den medicinska 
 behandlingen gjort att du fått ekonomiska svårigheter? 1 2 3 4 
 
 
Sätt en ring runt den siffra mellan 1 och 7 som stämmer bäst in på dig för  
följande frågor: 
 
29. Hur skulle du vilja beskriva din hälsa totalt sett under den vecka som gått? 
 
  1 2 3 4 5 6 7 
 
 Mycket dålig      Utmärkt 
 
 
30. Hur skulle du vilja beskriva din totala livskvalitet under den vecka som gått? 
 
  1 2 3 4 5 6 7 
 







EORTC  QLQ – CIPN20  
 
 
Patienter fortæller undertiden, at de har følgende symptomer eller problemer. Anfør venligst, i 
hvilket omfang du har haft disse symptomer eller problemer inden for den forløbne uge. Besvar 
spørgsmålene ved at sætte en ring omkring det tal, som passer bedst til dig. 
 
 
I den forløbne uge: Slet Lidt En del Meget 
  ikke 
 
31. Har du haft en prikkende fornemmelse i fingre eller hænder? 1 2 3 4 
32. Har du haft en prikkende fornemmelse i tæer eller fødder?  1 2 3 4 
33. Har du været følelsesløs i fingre eller hænder?  1 2 3 4 
34. Har du været følelsesløs i tæer eller fødder? 1 2 3 4 
35. Har du haft en jagende eller brændende smerte i fingre  
 eller hænder? 1 2 3 4 
36. Har du haft en jagende eller brændende smerte i tæer  
 eller fødder?  1 2 3 4 
37. Har du haft kramper i dine hænder? 1 2 3 4 
38. Har du haft kramper i dine fødder? 1 2 3 4 
39. Har du haft problemer med at stå eller gå på grund af besvær  
 med at mærke underlaget under dine fødder? 1 2 3 4 
40. Har du haft svært ved at skelne mellem varmt og koldt vand? 1 2 3 4 
41. Har du haft problemer med at skrive fordi du ikke kunne holde  
 ordentligt på en blyant eller en kuglepen? 1 2 3 4 
42. Har du haft svært ved at håndtere små ting med dine fingre 
 (f.eks. knappe små knapper)? 1 2 3 4 
43. Har du haft svært ved at åbne syltetøjsglas eller flasker fordi  
 du manglede kræfter i hænderne? 1 2 3 4 
44. Har du haft svært ved at gå, fordi du har en drop-fod  
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I den forløbne uge: Slet Lidt En del Meget 
  ikke 
   
45. Har du haft svært ved at gå opad trapper eller rejse dig fra en  
 stol fordi du manglede kræfter i dine ben? 1 2 3 4 
 
46. Har du været svimmel efter at du rejste dig fra siddende eller  
 liggende stilling? 1 2 3 4 
47. Har du haft sløret syn? 1 2 3 4 
48. Har du haft besvær med at høre?  1 2 3 4 
 
 
Besvar venligst kun følgende spørgsmål, hvis du kører bil: 
 
49. Har du haft besvær med at betjene pedalerne?  1 2 3 4 
 
 
Besvar venligst kun følgende spørgsmål, hvis du er en mand: 
 






EORTC QLQ-CIPN20  
En del pasienter opplever av og til at de har noen av følgende symptomer eller problemer. Vær 
vennlig å angi i hvilken grad du har hatt disse symptomene eller problemene i løpet av den siste 
uka. Sett en ring rundt det tallet som best beskriver din tilstand. 
 
I løpet av den siste uka: Ikke i det Litt En del Svært 
   hele tatt   mye 
31.  Har du hatt kribling i fingre eller hender? 1 2 3 4 
32.  Har du hatt kribling i tær eller føtter?  1 2 3 4 
33.  Har du hatt nummenhet i fingre eller hender? 1 2 3 4 
34.  Har du hatt nummenhet i tær eller føtter? 1 2 3 4 
35.  Har du hatt ilende eller brennende smerte i dine  
 fingre eller hender?  1 2 3 4 
36.  Har du hatt ilende eller brennende smerte i dine tær  
 eller føtter? 1 2 3 4 
37.  Har du hatt kramper i dine hender?  1 2 3 4 
38.  Har du hatt kramper i dine føtter?  1 2 3 4 
39.  Har du hatt problemer med å stå eller gå p.g.a.  
 vanskeligheter med å føle bakken under dine føtter?  1 2 3 4 
40.  Har du hatt vanskelig for å skille mellom varmt og  
 kaldt vann?  1 2 3 4 
41.  Har du hatt vanskeligheter med å skrive p.g.a. at du har  
 hatt problemer med å holde en penn?  1 2 3 4 
42.  Har du hatt vanskeligheter med å håndtere små gjenstander  
 med fingrene (f. eks. kneppe små knapper)? 1 2 3 4 
43.  Har du hatt vanskeligheter med å åpne et glass med skrukork  
 eller en flaske p.g.a. kraftløshet i hendene?  1 2 3 4 
44.  Har du hatt vanskeligheter med å gå p.g.a. at føttene dine  
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I løpet av den siste uka: Ikke i det Litt En del Svært 
   hele tatt   mye 
45.  Har du hatt vanskeligheter med å gå i trapper eller reise  
 deg fra en stol p.g.a. kraftløshet i bena? 1 2 3 4 
46.  Har du blitt svimmel når du har reist deg fra en sittende  
 eller liggende stilling? 1 2 3 4 
47.  Har du hatt uklart syn?  1 2 3 4 
48.  Har du hatt vanskelig for å høre? 1 2 3 4 
 
Vennligst svar på følgende spørsmål kun dersom du kjører bil: 
49.  Har du hatt vanskeligheter med å bruke pedalene?  1 2 3 4 
 
Vennligst svar på følgende spørsmål kun dersom du er mann: 
50.  Har du hatt vanskeligheter med å få eller opprettholde en  





EORTC QLQ – CIPN20  
 
 
Patienter berättar ibland att de har följande symtom eller problem. Markera i vilken utsträckning som 
du har haft dessa symptom eller problem under den senaste veckan. Svara genom att ringa in den 
siffra som bäst passar in på dig. 
 
 
Under veckan som gått: Inte Lite En hel Mycket 
 alls  del 
      
31. Har du haft stickningar i fingrar eller händer? 1 2 3 4 
      
32. Har du haft stickningar i tår eller fötter? 1 2 3 4 
      
33. Har du haft domningar i fingrar eller händer? 1 2 3 4 
      
34. Har du haft domningar i tår eller fötter? 1 2 3 4 
      
35. Har du haft ilande eller brännande smärta i fingrar eller händer? 1 2 3 4 
      
36. Har du haft ilande eller brännande smärta i tår eller fötter? 1 2 3 4 
      
37. Har du haft kramp i händerna? 1 2 3 4 
      
38. Har du haft kramp i fötterna? 1 2 3 4 
      
39. Har du haft problem med att stå eller gå på grund av att det var  
 svårt att känna underlaget under fötterna? 1 2 3 4 
      
40. Har du haft svårt att känna skillnaden mellan varmt och  
 kallt vatten? 1 2 3 4 
      
41. Har du haft problem med att hålla i en penna och därmed haft  
 svårt att skriva? 1 2 3 4 
      
42. Har du haft svårt att hantera små föremål med fingrarna  
 (t.ex. att knäppa små knappar)? 1 2 3 4 
      
43. Har du haft svårt att öppna en burk eller flaska på grund av  
 svaghet i händerna? 1 2 3 4 
      
44. Har du haft svårt att gå på grund av droppfot (som om framfoten  
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Under veckan som gått: Inte Lite En hel Mycket 
 Alls  del 
     
45. Har du haft svårt att gå uppför trappor eller att resa dig från en  
 stol på grund av svaghet i benen? 1 2 3 4 
      
46. Har du känt yrsel då du stigit upp från sittande eller liggande  
 ställning? 1 2 3 4 
      
47. Har du haft dimsyn? 1 2 3 4 
      
48. Har du haft svårt att höra? 1 2 3 4 
     
 
Besvara följande fråga endast om du kör bil:     
     
49. Har du haft svårt att använda pedalerna? 1 2 3 4 
     
 
Besvara följande fråga endast om du är en man:     
     
50. Har du haft svårt att få eller bibehålla en erektion? 1 2 3 4 
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Nedenfor er anført en række udsagn, som andre mennesker med din sygdom har sagt, er vigtige.  
Ved at sætte en ring omkring ét af tallene i hver linie, bedes du angive, hvor sandt hvert enkelt 
















       
B1 Jeg bliver let forpustet ............................................................. 0 
 
 1 2 3 4 
 
L2 Jeg har hostet ........................................................................... 0 
 
 1 2 3 4 
 
L3 Jeg har trykken i brystet .......................................................... 0 
 
 1 2 3 4 
 
L4 Jeg har let ved at trække vejret ................................................ 0 
 
 1 2 3 4 
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Nedenfor finner du en liste med uttalelser som andre mennesker med samme sykdom som deg 
mener er av betydning. Sett ring rundt eller merk av ett tall per linje for å angi svaret ditt, slik 




 Ikke i 
det hele 
tatt 
Litt Til en 
viss 
grad 
Mye Svært  
mye 
 
       
B1 Jeg har vært kortpustet ............................................................ 0 
 
1 2 3 4 
 
L2 Jeg hoster ................................................................................. 0 
 
1 2 3 4 
 
L3 Jeg føler stramming i brystet ................................................... 0 
 
1 2 3 4 
 
L4 Jeg kan puste uten vanskeligheter ........................................... 0 
 
1 2 3 4 
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Nedan finner du en lista med uttalanden som andra människor med din sjukdom tycker är viktiga.  














       
B1 Jag har varit andfådd ............................................................... 0 
 
0 1 2 3 4 
 
L2 Jag har hostat ........................................................................... 0 
 
0 1 2 3 4 
 
L3 Jag känner tryck över bröstet .................................................. 0 
 
0 1 2 3 4 
 
L4 Jag har lätt för att andas........................................................... 0 
 
0 1 2 3 4 
 
